ST6GALNAC4: A Potential Drug Target and Biomarker for Cancer and Neurodegenerative Diseases

Target Name: ST6GALNAC4

NCBI ID: G27090

ST6GALNAC4

Other Name(s): Sialyltransferase 3C | ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-sialyltransferase 4, transcript variant 1 | ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-sialyltransferase 4 | ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 4 | ST6 GalNAc alpha-2,6-sialyltransferase 4 | ST6GalNAc | SIA7D_HUMAN | Sialyltransferase 7D | SIAT3-C | NeuAc-alpha-2,3-Gal-beta-1,3-GalNAc-alpha-2, 6-sialyltransferase alpha2,6-sialyltransferase | SIAT3C | NeuAc-alpha-2,3-Gal-beta-1,3-GalNAc-alpha-2,6-sialyltransferase IV | ST6GalNAcIV | sialyltransferase 7D ((alpha-N-acetylneuraminyl-2,3-beta-galactosyl-1,3)-N-acetyl galactosaminide alpha-2,6-sialyltransferase) | sialyltransferase 3C | ST6GALNAC4 variant 1 | Alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3-N-acetyl-galactosaminide alpha-2,6-sialyltransferase | Sialyltransferase 7D ((alpha-N-acetylneuraminyl-2,3-beta-galactosyl-1,3)-N-acetyl galactosaminide alpha-2,6-sialyltransferase) | SIAT7D | NeuAc-alpha-2,3-Gal-beta-1,3-GalNAc-alpha-2,6-sialyltransferase | ST6GALNACIV | NeuAc-alpha-2,3-Gal-beta-1,3-GalNAc-alpha-2,6-sialyltransferase IV (isoform a) | ST6 neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminidealpha-2,6-sialyltransferase 4 | IV | ST6GalNAc IV | OTTHUMP00000197015 | SIAT7-D

ST6GALNAC4: A Potential Drug Target and Biomarker for Cancer and Neurodegenerative Diseases

Sialyltransferase 3C (ST6GALNAC4) is a protein that is expressed in many different tissues throughout the body, including the brain, heart, and liver. It is a member of the GALNAC family of enzymes, which are involved in the transfer of sialyl groups to cell surface glycoligands. This protein is of particular interest as a potential drug target or biomarker because of its role in the development and progression of certain diseases.

One of the key functions of ST6GALNAC4 is its role in the development and progression of certain types of cancer. For example, studies have shown that high levels of ST6GALNAC4 are associated with the development of pancreatic cancer, and that inhibiting this enzyme has been shown to be a promising strategy for treating this disease. Additionally, ST6GALNAC4 has also been shown to be involved in the development of other types of cancer, including breast, ovarian, and colorectal cancer.

Another potential function of ST6GALNAC4 is its role in the development of neurodegenerative diseases. Studies have shown that ST6GALNAC4 is involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Additionally, this protein has been shown to be involved in the development of certain neurological conditions, such as ALZHEIMER'S DISORDER and multiple sclerosis.

In addition to its role in the development and progression of certain diseases, ST6GALNAC4 is also of interest as a potential drug target. Studies have shown that inhibiting this enzyme have been shown to be effective in treating certain diseases, including cancer and neurodegenerative diseases. For example, studies have shown that inhibiting ST6GALNAC4 has been shown to be effective in treating certain types of cancer, such as pancreatic cancer and breast cancer. Additionally, this protein has also been shown to be involved in a number of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease, and inhibiting it has been shown to be effective in treating these conditions.

Furthermore, ST6GALNAC4 is also of interest as a potential biomarker. Its expression has been shown to be associated with the development and progression of certain diseases, including cancer and neurodegenerative diseases. Additionally, this protein has been shown to be involved in the development of certain neurological conditions, such as ALZHEIMER'S DISORDER and multiple sclerosis, and its levels have been shown to be associated with the progression of these conditions.

In conclusion, ST6GALNAC4 is a protein that is of particular interest as a potential drug target or biomarker due to its role in the development and progression of certain diseases. Its expression has been shown to be associated with the development and progression of cancer and neurodegenerative diseases, and its inhibition has been shown to be effective in treating these conditions. Further research is needed to fully understand the role of ST6GALNAC4 in these diseases and to develop safe and effective treatments.

Protein Name: ST6 N-acetylgalactosaminide Alpha-2,6-sialyltransferase 4

Functions: Transfers the sialyl group (N-acetyl-alpha-neuraminyl or NeuAc) from CMP-NeuAc to the GalNAc residue on the NeuAc-alpha-2,3-Gal-beta-1,3-GalNAc sequence of glycoproteins and glycolipids forming an alpha-2,6-linkage. Produces branched type disialyl structures by transfer of a sialyl group onto a GalNAc residue inside the backbone core chains. Prefers O-glycans to glycoproteins or glycolipids

The "ST6GALNAC4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ST6GALNAC4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets